Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-fucosyllactose + Bifidobacterium longum subsp. infantis EFEL8008
- Development stage
- Preclinical
- Lead developer
- Seoul National University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This drug is a synbiotic combination consisting of the human milk oligosaccharide (HMO) **2'-fucosyllactose (2'-FL)** as the prebiotic component and the probiotic strain **Bifidobacterium longum subsp. infantis EFEL8008**. Designed as a live biotherapeutic product (LBP) for oral administration, it targets the modulation of the adult gut microbiota to address gut dysbiosis. The 2'-FL component is highly resistant to upper gastrointestinal digestion, allowing it to reach the colon where it selectively serves as a substrate for the EFEL8008 strain. In vitro studies have demonstrated that this synbiotic significantly increases the abundance of *Bifidobacterium*, improves microbial diversity, and enriches beneficial commensal taxa such as *Lactobacillus* while reducing potential pathogens. Furthermore, the treatment markedly enhances the production of beneficial short-chain fatty acids (SCFAs)—including acetate, propionate, lactate, and butyrate—and suppresses the formation of trimethylamine (TMA), a metabolite associated with cardiovascular risk.
- Other names
- 2'-FL + B. infantis EFEL80082'-fucosyllactose + Bifidobacterium longum subsp. infantis EFEL8008 synbiotic
Beyond the preview
Go deeper on 2'-fucosyllactose + Bifidobacterium longum subsp. infantis EFEL8008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2'-fucosyllactose + Bifidobacterium longum subsp. infantis EFEL8008.